MorphoSys AG
(NASDAQ:MOR)
$17.66
0.18[1.03%]
At close: Feb 20
$17.66
0[0.00%]
After Hours: 9:30AM EDT
Open17.670Close17.590
Vol / Avg.1.142M / 2.680MMkt Cap2.656B
Day Range17.550 - 17.77052 Wk Range3.650 - 17.870

MorphoSys Stock (NASDAQ:MOR), Quotes and News Summary

MorphoSys Stock (NASDAQ: MOR) stock price, news, charts, stock research, profile.

Open17.670Close17.590
Vol / Avg.1.142M / 2.680MMkt Cap2.656B
Day Range17.550 - 17.77052 Wk Range3.650 - 17.870
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
ACCESSWIRE - Feb 5, 2024, 5:15PM
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Business Wire - Feb 5, 2024, 4:46PM
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
ACCESSWIRE - Jan 30, 2024, 3:15AM
Thinking about buying stock in Morphosys, Iovance Biotherapeutics, Bank of America, Energy Fuels, or China Recycling Energy Corporation?
PRNewswire - Jan 16, 2024, 9:31AM
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ACCESSWIRE - Jan 8, 2024, 2:20AM
MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Business Wire - Dec 10, 2023, 7:31PM
Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
ACCESSWIRE - Nov 20, 2023, 4:50PM
MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Business Wire - Nov 20, 2023, 4:30PM
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
Business Wire - Nov 15, 2023, 4:01PM
Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
ACCESSWIRE - Nov 9, 2023, 4:20PM
Full archive of press releases available on Benzinga Pro
Sector: Health Care.Industry: Biotechnology

Earnings

see more
Q1 2024Est.ActualSurprise
EPS
(EXPECTED)
REV
Q4 2023Est.ActualSurprise
EPS
(EXPECTED)
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
2024-02-05Wells FargoDerek ArchilaReiteratesOverweightOverweightMaintains-17.00
2024-01-19Morgan StanleyJames QuigleyDowngradesOverweightEqual-Weight---
2024-01-16Morgan StanleyJames QuigleyDowngradesOverweightEqual-Weight---
2023-12-15Wells FargoDerek ArchilaMaintainsOverweightOverweightRaises10.0017.00

Related Companies

TickerCompanyChg %Mkt Cap
MORMorphoSys0%2.7B
IDYAIDEAYA Biosciences0%3.2B
TWSTTwist Bioscience0%2.3B
MLTXMoonLake0%3.3B
TGTXTG Therapeutics0%2B
Q

How do I buy MorphoSys (MOR) stock?

A

You can purchase shares of MorphoSys (NASDAQ: MOR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are MorphoSys's (MOR) competitors?

Q

What is the target price for MorphoSys (MOR) stock?

A

The latest price target for MorphoSys (NASDAQ: MOR) was reported by Wells Fargo on Monday, February 5, 2024. The analyst firm set a price target for 17.00 expecting MOR to fall to within 12 months (a possible -3.74% downside). 12 analyst firms have reported ratings in the last year.

Q

Current Stock Price for MorphoSys (MOR)?

A

The stock price for MorphoSys (NASDAQ: MOR) is $17.66 last updated Today at February 20, 2024 at 9:30 AM EST.

Q

Does MorphoSys (MOR) pay a dividend?

A

There are no upcoming dividends for MorphoSys.

Q

When is MorphoSys (NASDAQ:MOR) reporting earnings?

A

MorphoSys’s Q1 earnings are confirmed for Wednesday, May 1, 2024.

Q

Is MorphoSys (MOR) going to split?

A

There is no upcoming split for MorphoSys.

Q

What sector and industry does MorphoSys (MOR) operate in?

A

MorphoSys is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.